Newer Hormonal Therapies in Prostate Cancer - prIME Oncology
Expert Review
Expert Review

Newer Hormonal Therapies in Prostate Cancer

Expert Insights Into Current and Emerging Uses

Not a member of My prIME? Join now for instant access.

This Expert Review features internationally-renowned thought leaders discussing current and emerging uses of next-generation androgen therapies in prostate cancer. Topics addressed include treatment strategies for castration-resistant and -sensitive prostate cancer, efficacy and safety of newer hormonal therapeutic options, and how to sequence these newer agents. This program also features companion downloadable slide decks that include key information covered in the discussions.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



0.75 AMA PRA Category 1 Credit

Release Date

Release Date

Dec 21, 2017

Expiration Date

Dec 21, 2018


  • Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
    University of Sheffield
    Weston Park Hospital
    Sheffield, United Kingdom


  • Karim Fizazi, MD, PhDGustave Roussy
    Villejuif, France
  • Bertrand Tombal, MD, PhDSt Luc University
    Brussels, Belgium

This educational activity is designed for medical oncologists, urologists, and other healthcare providers involved in the management of patients with prostate cancer.

After successful completion of this educational activity, participants should be able to:

  • Develop optimal treatment strategies that incorporate newer hormonal therapeutic options for castration-resistant and -sensitive prostate cancer
  • Recognize potential adverse events associated with newer hormonal therapeutic options used to treat prostate cancer
  • Describe data regarding the efficacy and safety of newer hormonal therapeutic options in endocrine-sensitive, metastatic and locally advanced prostate cancer

This educational activity is supported by a grant from Astellas.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Newer Hormonal Therapies in Prostate Cancer - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you.

Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Fizazi has disclosed that he has received consulting fees and is on the membership board for Amgen; Astellas Pharma, Inc; Bayer HealthCare Pharmaceuticals; Janssen Pharmaceuticals; MSD; Orion Pharma; and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Tombal has disclosed that he has received consulting fees from Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Ferring Pharmaceuticals, and Janssen Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP (medical content reviewer/planner) – contracted research or research support from Amgen and Bayer
  • Sanneke Koekkoek, RN (clinical content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.